Home Jurisdiction: ___________________________________________________________ [ ] 1. Form 69 – CIS full ( completed by Qualifying CIS Operator ) [ ] 2.* Standard letter issued by the Home Regulator to a
: ______________________________________________ Home Jurisdiction: ___________________________________________________________ [ ] 1. Form 69 – CIS full (completed by Qualifying CIS Operator) [ ] 2.* Standard letter issued by the Home Regulator
Ventures 2nd Quarter 2019 MD&A 1 ข่าวด่วน; บริษัทประกาศการเข้าซ้ือกจิการปลายน า้ขนาดใหญ่ในธุรกจิ Integrated Oxides and Derivatives ซ่ึงได้รับประโยชน์จากการตั้งอยู่ที ่Gulf Coast ประเทศ สหรัฐอเมริกา บริษทั อ
176.1MB, or 13.7 % the mainly reason was that the company invested in the project for Q1–2018, but it can not get payment from those project that had been implemented but not yet completed which those
and Baht 100 million for construction projects. The captioned capital increase is expected to be completed on December 29, 2017. Construction Income In the 3rd quarter of 2017, the company and its
% decrease since there has been no any new awarded project and such an income has been gained from 9 projects on hand since 2016 and another 3 projects completed in 2017. The 2017income of Baht 72.04 million
recognized the revenue by completed segment but not yet completed which those reached the invoice. As a consequence, trade receivables decreased, resulting in an increase unbilled receivables. Unbilled
แบบแจ้งชื่อผู้บริหารของบริษัท “Fill in Form 35-E1 via the SEC electronic filing system only. Then, print out the completed form, affix the authorized signature and submit the hardcopy to the SEC
collaboration to prevent and suppress securities-related offenses, setting the stage for more integrated efforts among justice-related agencies to take swifter and stronger legal action against offenders.SET
outsourced production with fully completed services, from formulation development, research, marketing and label design and packaging services, including cosmetic product filings with the Food and Drug